Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. Methods Data were pooled from patients with moderately to severely ac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2019-09, Vol.71 (9), p.1450-1459
Hauptverfasser:	Charles‐Schoeman, Christina, DeMasi, Ryan, Valdez, Hernan, Soma, Koshika, Hwang, Lie‐Ju, Boy, Mary G., Biswas, Pinaki, McInnes, Iain B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Arthritis Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Blood Sedimentation Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cerebral infarction Cholesterol Cholesterol - blood Cholesterol, HDL - blood Cholesterol, LDL - blood Clinical Trials, Phase III as Topic Confidence intervals Density Erythrocyte sedimentation rate Erythrocytes Female Glucocorticoids Health risk assessment Health risks High density lipoprotein Humans Hypertension Incidence Low density lipoprotein Male Middle Aged Myocardial infarction Myocardial Infarction - epidemiology Myocardial Infarction - etiology Original Patients Piperidines - therapeutic use Proportional Hazards Models Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Pyrroles - therapeutic use Regression analysis Regression models Rheumatoid Arthritis Risk analysis Risk Factors Sedimentation Statistical analysis Stroke - epidemiology Stroke - etiology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!